



## The Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment) Regulations, 2019

|                               |                                |
|-------------------------------|--------------------------------|
| <i>Made</i>                   | 15 <sup>th</sup> January, 2019 |
| <i>Coming into operation</i>  | 16 <sup>th</sup> January, 2019 |
| <i>Laid before the States</i> | , 2019                         |

THE COMMITTEE FOR EMPLOYMENT & SOCIAL SECURITY, in exercise of the powers conferred on it by sections 10 and 35 of the Health Service (Benefit) (Guernsey) Law, 1990<sup>a</sup> and section 1 of the Health Service (Benefit) (Limited Lists) Ordinance, 2004<sup>b</sup>, and all other powers enabling it in that behalf, hereby makes the following Regulations:-

### Amendment to the 2004 Regulations.

1. In the Schedule to the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) Regulations, 2004<sup>c</sup> ("**the Schedule**") -

---

<sup>a</sup> Ordres en Conseil Vol. XXXII, p. 192; Vol. XLIII(1), p. 246; Order in Council No. II of 2011; Recueil d'Ordonnances Tome XXVI, pp. 177, 483, and 495; Tome XXIX, pp. 182, 373, 406 and 580 and modified by Tome XXVI, pp. 484 and 491 and 495; Tome XXVII, p. 200; Tome XXVIII, p. 1; Tome XXIX, pp. 182, 196, 200 and 210; Tome XXXI, p. 628 and Tome XXXII, p. 628, Ordinance No. XXXIV of 2013, and Ordinance No. XXV of 2017. Extended to Alderney with modification by Recueil d'Ordonnances Tome XXV, p. 204.

<sup>b</sup> Recueil d'Ordonnances Tome XXIX, p. 441.

<sup>c</sup> G.S.I. No. 9 of 2004 as amended by G.S.I. No. 42 of 2004; No's 18, 25 and 38 of 2005; No's 11, 18, 26, 36 and 46 of 2006; No's 3, 5, 6, 16, 17 and 32 of 2007; No's 11, 23, 29, 31, 47, 50 and 76 of 2008; No's 16, 35, 43, 47 and 56 of 2009; No's 5, 32, 48, 88, 91 and 99 of 2010; No's 5, 13, 19, 37, 38 and 52 of 2011; No's 5, 25, 33 and 52 of 2012; No's 5, 27, 35, 42, 68, 78 and 87 of 2013; No's 8, 11, 16, 25, 57, 69 and 99 of 2014, No's 9, 33 and 106 of 2015, No's. 10, 17, 25, 31 and 49 of 2016; No's. 48, 69, 78, 88 and 117 of 2017 and No. 6, 9, 16, 28, 35, 40 and 43 of 2018.

- (a) insert the rows set out in Schedule 1 to these Regulations in the appropriate places and under the appropriate headings, as set out in the Schedule, and
- (b) substitute the entry relating to Adalimumab in the row of the Schedule referred to in columns 1 and 2 of Schedule 2 to these Regulations for the appropriate entry set out in column 3 of Schedule 2 to these Regulations.

**Citation, commencement and extent.**

2. (1) These Regulations may be cited as the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment) Regulations, 2019, and shall come into force on the 16<sup>th</sup> day of January, 2019.

(2) These Regulations shall have effect in the Islands of Guernsey, Alderney, Herm and Jethou.

Dated this 15<sup>th</sup> day of January, 2019.



M. K. LE CLERC

President of the States Committee for Employment & Social Security

For and on behalf of the Committee

## SCHEDULE 1

## ROWS TO BE INSERTED IN THE SCHEDULE TO THE 2004 REGULATIONS

| British National Formulary (BNF) Section | Heading                       | Pharmaceutical Benefit   |
|--|-------------------------------|--|
| 2.5.1                                    | Vasodilator antihypertensives | Bosentan monohydrate tab 62.5mg, 125mg (For specialist initiation in systemic sclerosis only and dispensed by PEH Pharmacy only)   |
| 5.2                                      | Antivirals                    | Tenofovir alafenamide tab 25mg (Personally initiated by on-island Consultant Virologist on the advice of the Multi-Disciplinary Team only)                                   |
| 5.2                                      | Antivirals                    | Emtricitabine / Tenofovir alafenamide Tab 200mg/25mg, 200mg/10mg (Personally initiated by on-island Consultant Virologist on the advice of the Multi-Disciplinary Team only) |
| 13.7.2                                   | Hirsutism                     | Eflornithine (as Eflornithine monohydrate chloride) 115mg per 1 gram of cream  |
| Appliances                               | Insulin Pump Accessories      | Omnipod Personal Diabetes Manager (central purchasing by Health & Social Care only)  |
| Appliances                               | Pessaries                     | Pessaries: Donut and Cube with holes (all available sizes)   |

SCHEDULE 2

ROW TO BE SUBSTITUTED IN THE SCHEDULE TO THE 2004 REGULATIONS

| British National<br>Formulary<br>(BNF) Section | Heading                          | Pharmaceutical Benefit   |
|--|----------------------------------|--|
| 10.1.3   | Rheumatic Disease<br>Suppressant | Adalimumab injection 40mg –<br>Humira <sup>®</sup> only (for use only under<br>specialist supervision) |

---

## EXPLANATORY NOTE

*(This note is not part of the Regulations)*

These Regulations add to the list of drugs and appliances that may be prescribed as pharmaceutical benefit and substitute one drug on that list with another form of the same drug.

These Regulations come into force on the 16<sup>th</sup> January, 2019.